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RESEARCH ARTICLE Open Access
Treatment of chronic migraine with
transcutaneous stimulation of the auricular
branch of the vagal nerve (auricular t-VNS): a
randomized, monocentric clinical trial
Andreas Straube1*, J. Ellrich2,3, O. Eren1, B. Blum1 and R. Ruscheweyh1
Abstract
Background: Aim of the study was assessment of efficacy and safety of transcutaneous stimulation of the auricular
branch of the vagal nerve (t-VNS) in the treatment of chronic migraine.
Methods: A monocentric, randomized, controlled, double-blind study was conducted. After one month of baseline,
chronic migraine patients were randomized to receive 25 Hz or 1 Hz stimulation of the sensory vagal area at the left
ear by a handhold battery driven stimulator for 4 h/day during 3 months. Headache days per 28 days were compared
between baseline and the last month of treatment and the number of days with acute medication was recorded The
Headache Impact Test (HIT-6) and the Migraine Disability Assessment (MIDAS) questionnaires were used to assess
headache-related disability.
Results: Of 46 randomized patients, 40 finished the study (per protocol). In the per protocol analysis, patients in the
1 Hz group had a significantly larger reduction in headache days per 28 days than patients in the 25 Hz group
(−7.0 ± 4.6 vs. −3.3 ± 5.4 days, p = 0.035). 29.4 % of the patients in the 1 Hz group had a ≥50 % reduction in headache
days vs. 13.3 % in the 25 Hz group. HIT-6 and MIDAS scores were significantly improved in both groups, without group
differences. There were no serious treatment-related adverse events.
Conclusion: Treatment of chronic migraine by t-VNS at 1 Hz was safe and effective. The mean reduction of headache
days after 12 weeks of treatment exceeded that reported for other nerve stimulating procedures.
Keywords: Sensory nerve; Neuromodulation; Clinical study; Chronic headache; Electrical pulses
Background
Migraine is a frequent neurological disorder. In some
patients, episodic migraine (with < 15 headache days per
month) evolves towards chronic migraine, which is char-
acterized by ≥15 headache days per month of which ≥ 8
have migraine-like features [1], see also: http://ihs-classi-
fication.org/de/0_downloads/. Chronic migraine affects
approximately 1.3 to 2.4 % of the general population [2].
It is associated with significant disability and reduced
health-related quality of life and often complicated by
overuse of acute pain medications [3, 4]. Up to now, ran-
domized controlled trials showing a significant effect in
the treatment specifically of chronic migraine have been
published only for topiramate and onabotulinumtoxin A
[5, 6]. Treatment of chronic migraine is often difficult,
with significant numbers of patients not responding to
pharmacological management.
In recent years, neuromodulation was introduced in the
treatment of headache [7]. Invasive occipital nerve stimu-
lation (ONS) has been investigated for the treatment of
chronic migraine, with inconsistent results [8–10]. Signifi-
cant reduction in headache days was demonstrated in only
one of the three studies, which however did not meet its
primary endpoint (a 50 % reduction of mean daily pain
ratings) [10]. A major disadvantage of ONS is the safety
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profile with frequent adverse events such as infections, lead
migration or lead disconnection [8, 10]. This is also the rea-
son why in some health markets the reimbursement of ONS
was stopped by the regulatory administration. Thus, less
invasive forms of neuromodulation such as transcutaneous
electrical nerve stimulation are under investigation. For ex-
ample, supraorbital transcutaneous stimulation for 3 months
has been shown to be effective for the preventive treatment
of episodic migraine (active treatment: 38 % responders,
sham: 12 % responders, p < 0.05) [11].
Vagal nerve stimulation using implanted electrodes is
used as a treatment option in otherwise therapy-
refractory epilepsy and depression [12]. Case reports and
small series of patients who received an implanted vagal
nerve stimulator for treatment of epilepsy and had comor-
bid migraine suggest that VNS may have a preventive ef-
fect in migraine [13–16]. A recently developed medical
device (NEMOS®, cerbomed, Erlangen, Germany) allows
for non-invasive, transcutaneous stimulation of the auricu-
lar branch of the vagus nerve (auricular t-VNS) using a
special ear electrode. Auricular t-VNS excites thick mye-
linated sensory Aβ-fiber afferents in the vagal nerve, acti-
vating the nucleus of the solitary tract [17, 18]. Effects on
autonomous activity have been demonstrated in healthy
subjects where auricular t-VNS increases heart rate vari-
ability [19]. Anticonvulsive effects in rodents are similar to
those achieved with invasive VNS [18]. Functional imaging
during auricular t-VNS has shown a pattern consistent
with afferent vagal stimulation [20, 21]. Both invasive VNS
and auricular t-VNS reduce pinprick and pressure pain in
humans [22, 23]. In addition, a recent observational study
has suggested that t-VNS to the right cervical branch of
the vagus nerve (cervical t-VNS) may be effective for acute
migraine treatment [24]. In the present study, we investi-
gated the effect of auricular t-VNS on chronic migraine.
Methods
This was a monocentric, prospective, double-blind, ran-
domized, parallel-group, controlled trial analyzed both
on intention-to-treat basis (ITT), and on per protocol
basis (PP). The trial was conducted in a German tertiary
headache outpatient clinic (Department of Neurology,
University of Munich). The study was approved by the
ethics committee of the medical faculty of the University of
Munich and written informed consent was obtained from
all participants. The study is registered in the German
Clinical Trials Register (DRKS00003681).
Study participants
Men or women between 18 and 70 years with a diagnosis
of chronic migraine according to the ICHD-IIR (code
A1.5.1.) (http://ihs-classification.org/de/0_downloads/), dur-
ation of ≥ 6 months, no migraine-prophylactic medication
or stable migraine-prophylactic medication for ≥1 month,
and stable acute medication were eligible, medication over-
use was not an exclusion criterion.
Patients were excluded if they suffered from other primary
or secondary headaches, severe neurologic or psychiatric
disorders including opioid- or tranquilizer-dependency,
cranio-mandibulary dysfunction, fibromyalgia, had a Beck’s
Depression Inventory (BDI [25]) score >25 at the screening
visit, anatomic or pathologic changes at the left outer ear,
currently participated in another clinical trial, or were unable
to keep a headache diary. Pregnant or breast-feeding women
were also excluded. A pregnancy test was performed at the
screening visit in women of childbearing potential and they
were required to use a reliable means of contraception. In
addition, patients who had less than 15 headache days per
28 days during the 4-week baseline period were excluded.
Study design (Fig. 1)
The study consisted of a 4-week screening period
(“baseline”) followed by a 12-week randomized, double-
blind, parallel-group treatment period with either 1 Hz
or 25 Hz tVNS with the NEMOS® device (Fig. 2). Ad-
verse events were recorded at visits 2 to 6. Compliance
with stimulation was checked at visits 3 to 6 by reading
out the NEMOS® device and quantified in percent of the
Fig. 1 Study design
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intended daily stimulation time (4 h). Re-training was ad-
ministered during visits 3 to 6 as necessary. The Migraine
Disability Assessment (MIDAS [26]) and the Headache
Impact Test (HIT-6 [27]) were filled in by the patient as
indicated in Fig. 1. Patients kept a paper-and-pencil head-
ache diary during the entire period, handing in their diaries
and receiving a fresh sheet at each visit. In the diary, pa-
tients indicated for every day (1) headache duration in
hours, (2) headache intensity (on a 0 to 10 numerical rating
scale: 0, no pain; 10, strongest pain imaginable), and (3)
intake of acute headache medication (analgesics, triptans).
Sample size calculations were based on published studies
on successful pharmacological treatment of chronic migraine
(mean effect size: −4,68 headache days/month after removal
of the placebo effect) [5, 6, 28, 29]. To detect an effect of this
size with an α error of 0.05 and a power of 0.80, a group size
of 49 patients per treatment group was estimated, including
10 % drop-out. An interims analysis after 46 patients was
planned. Since patient recruitment was slower than ex-
pected, the sponsor decided to terminate the study at the
interims analysis, and no further patients were enrolled.
Neurostimulation
The NEMOS® t-VNS device (Cerbomed, Erlangen, Germany)
is a transcutaneous vagus nerve stimulator designed for
electrical stimulation at the concha of the outer ear, which
receives sensory innervation from the auricular branch of the
vagal nerve (Fig. 2). The NEMOS® device has received the
CE mark for treatment of pain (CE0408) and is registered in
the European Databank on Medical Devices (EUDAMED,
CIV-11-09-002381). It consists of a handheld, battery driven
electrical stimulator connected to an ear electrode placed in
contact with the skin of the concha. Impedance is measured
automatically and insufficient electrode contact with the skin
evokes an alarm. During stimulation, series of electrical
pulses (pulse width: 250 μs, frequency: 1 Hz or 25 Hz, duty
cycle: 30s on, 30 s off, to avoid habituation) are applied to
the skin of the concha. Stimulus intensity was individually fit-
ted during visit 2 to elicit a tingling but not painful sensation,
and could later be adjusted by the patient as needed. Patients
were asked to stimulate for a total of 4 h per day (in sessions
of 1 to 4 h, a specific distribution over the day or interval be-
tween sessions was not required), and were free to stimulate
for an additional hour if they thought this was useful, e.g. for
treatment of acute headache. The effect of such acute treat-
ment was not recorded. Stimulation parameters of the 25 Hz
group were chosen so that with 4 h of daily stimulation, the
number of electrical stimuli per day would be similar to
those normally used for invasive vagal nerve stimulation in
patients with epilepsy. The 1 Hz stimulation was intended as
an active control. The active control was chosen in order to
avoid un-blinding of the subjects.
Primary and secondary outcome parameters
All outcome measures refer to change from baseline (the
4-week period between visits 1 and 2) to the evaluation
period (the 4-week period between visits 5 and 6, Fig. 1).
The primary outcome measure was mean change in head-
ache days per 28 days. A headache day was defined as a
calendar day with headache of ≥ 4 h duration or headache
successfully aborted by acute headache medication or any
other treatment known to be typically effective in the spe-
cific patient (e.g. sleep, progressive relaxation exercises).
Secondary outcome parameters were: (1) percentage of
“responders” (subjects having at least 50 % reduction of
headache days per 28 days from baseline to evaluation); (2)
change in mean headache intensity on days with headache;
(3) change in days with acute headache medication intake
per 28 days; (4) change in headache-related disability, as
assessed by the MIDAS and HIT-6 questionnaires; (5) num-
ber and type of adverse events.
Statistical analysis
Mean± standard deviation (SD) is reported unless stated
otherwise. The threshold for significance of statistical com-
parisons was set at p < 0.05. Statistical analysis was performed
both on ITTand on per protocol basis (PP). For the ITTana-
lysis, a last observation carried forward approach was used
for patients who dropped out during the course of the study.
Group comparisons at baseline, of duration of the treat-
ment period, compliance or number of patients affected by
adverse events were done using Mann–Whitney U-Test or
Fisher’s exact test as appropriate. Analysis of the primary
endpoint was done using an analysis of covariance
(ANCOVA) model with the factors treatment group (1 Hz
vs. 25 Hz) and sex as categorical variables and baseline
Fig. 2 NEMOS® device and positioning of the electrode for stimulation
of the vagus afferents at the concha
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values as covariate. The same type of ANCOVA was used
for the analysis of the following secondary outcome param-
eters: change in mean headache intensity, change in days
with acute headache medication intake per 28 days and
change in MIDAS and HIT-6 scores. The number of
responders was compared between groups using a logistic
regression model that included treatment group and sex as
factor and the number of headache days per 28 days at
baseline as covariate. An estimate of the treatment odds
ratio (Wald method) was derived from this model.
Results
The study was conducted between March 2012 and July
2014. A total of 46 patients were randomized to the 1 Hz
group (n = 22) or the 25 Hz group (n = 24, ITT). 6 patients
dropped out during the study. Reasons for dropouts were:
adverse events in 4 patients (treatment-related stimulation
site ulcer in 3 patients, gastrectomy not related to treatment
in 1 patient), insufficient compliance in 1 patient, patient’s
request in 1 patient. One additional patient was excluded
from the per protocol (PP) analysis after the end of the
study because of violation of inclusion criteria (<15 head-
ache days per 28 days in the screening period). This left 17
patients in the 1 Hz group and 22 patients in the 25 Hz
group for the PP analysis (Fig. 3) Demographic and head-
ache characteristics of the population are shown in Table 1.
There were no significant differences between both groups.
Primary outcome measure
PP-analysis indicated a significant decrease in headache
days per 28 days from baseline to evaluation, which was
significantly larger in the 1 Hz group than in the 25 Hz group
(F[35] = 4.82, p= 0.035, Table 2). In the 1 Hz group, the re-
duction amounted to −7.0 days per 28 days (36.4 % reduction
from baseline), while the 25 Hz group reached only −3.3 days
(17.4 % reduction from baseline). In the ITT analysis, there
also was a significant decrease in headache days per 28 days
in both groups, but no significant group difference (F[42] =
2.94, p= 0.094, Table 2). Visual inspection of headache days
per 28 days over the treatment period revealed a continuous
decrease in the 1 Hz group, while a steady state was reached
after 14 days in the 25 Hz group (Fig. 4).
Secondary outcome measures
Results of secondary outcome measures and the correspond-
ing statistics are summarized in Table 2. The number of
responders (>50 % improvement in headache days) was in
the 1 Hz group (PP) 29.4 % and in the 25 Hz group (PP)
13.6 %. Headache intensity was not significantly changed by
t-VNS in either treatment group, and there were no group
differences. The number of days with intake of acute head-
ache medication as well as the MIDAS and HIT-6 scores
were significantly reduced in both treatment groups, there
were no group differences.
Treatment duration and compliance
Results and statistics are listed in Table 3. Duration of
the treatment period was similar between groups. The
average number of stimulated hours per day during the
treatment period was around 3.4 in all groups, corre-
sponding to around 85 % of the requested 4 h of daily
Fig. 3 Patient disposition
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stimulation, indicating good compliance with treatment.
There were no significant group differences.
Safety and tolerability
Adverse events (AEs) were analysed in the full analysis set
(safety set) and summarized in Table 4. The number of
treatment emergent AEs (AEs occurring after initiation of
treatment) was higher in the 25 Hz group (112 events, 76
treatment-related events) as compared to the 1 Hz group
(67 events, 39 treatment-related events, Table 4),. Most AEs
were mild or moderate in severity and resolved without
sequelae. The most frequent treatment-related AE were
local problems at the stimulation site, such as mild or
moderate pain, paresthesia, or pruritus during or after
stimulation, and erythema, ulcer or scab (31 events in 10
patients in the 1 Hz group, 70 events in 17 patients in the
25 Hz group, p= 0.14). Treatment-related AEs leading to
discontinuation of the study were stimulation site ulcer
(accompanied by pain, paresthesia, or pruritus) in 2 patients
of the 1 Hz group and in 1 patient of the 25 Hz group.
These three cases of application site ulcer occurred early
during the study. After that, patients were asked to specially
care for the skin of their ear after each use of the NEMOS®
device, using a custom rich skin cream, and no more cases
of application site ulcer occurred. There were no treatment-
related SAEs. Three SAEs, leading to hospitalization of the
patient, were recorded during the whole study (infectious
mononucleosis, gastrectomy, intervertebral disc protrusion).
Discussion
The present monocentric, randomized, controlled, double-
blind, parallel-group clinical trial provides evidence that
Table 1 Baseline characteristics of the cohort
Intention-to-treat analysis Per protocol analysis
1 Hz (n = 22) 25 Hz (n = 24) Group comparison 1 Hz (n = 17) 25 Hz (n = 22) Group comparison
Age 43.8 ± 11.5 39.3 ± 12.4 p = 0.21 44.1 ± 11.4 39.0 ± 12.5 p = 0.21
Females 18 21 p = 0.69 13 19 p = 0.68
Headache days/28 days 19.4 ± 4.0 18.9 ± 5.1 p = 0.47 19.1 ± 3.7 19.2 ± 4.7 p = 0.66
Headache intensity (NRS: 0–10) 5.2 ± 1.5 5.0 ± 1.5 p = 0.73 5.0 ± 1.5 5.0 ± 1.5 p = 0.98
Migraine history (years) 27.1 ± 13.0 20.4 ± 12.1 p = 0.08 27.8 ± 11.5 21.4 ± 12.1 p = 0.11
Days with acute headache medication/28 days 10.3 ± 6.4 8.2 ± 4.9 p = 0.24 11.1 ± 6.6 8.6 ± 4.8 p = 0.17
MIDAS score 76.8 ± 64.8 83.6 ± 56.0 p = 0.55 77.2 ± 70.1 82.1 ± 58.0 p = 0.71
HIT-6 score 64.3 ± 4.7 66.0 ± 4.1 p = 0.25 64.8 ± 5.0 66.0 ± 4.2 p = 0.55
BDI 6.9 ± 5.7 7.9 ± 5.6 p = 0.59 6.9 ± 5.9 7.2 ± 5.0 p = 0.95
Demographic and headache characteristics assessed at the first visit or during the baseline period (4 weeks) are given. Values are mean ± SD or numbers of
subjects. Results of Mann–Whitney U test or Fisher’s Exact test are given. Headache intensity (NRS: numerical rating scale 0–10)
MIDAS migraine disability assessment, HIT headache impact test, BDI beck’s depression inventory
Table 2 Results of primary and secondary treatment outcome measures
Intention-t-treat analysis Per protocol analysis
1 Hz (n = 22) 25 Hz (n = 24) Group comparison 1 Hz (n = 17) 25 Hz (n = 22) Group comparison
Change in headache days/28 days −5.6 ± 5.0 −3.0 ± 5.3 F[42] = 2.94 −7.0 ± 4.6 −3.3 ± 5.4 F[35] = 4.82
(−5.9; −0.5) (−8.5; −3.2) p = 0.094 (−9.6; −4.1) (−5.9; −0.4) p = 0.035
Responder (50 % reduction in
headache days)
5 (22.7 %) 3 (12.5 %) OR = 2.44 5 (29.4 %) 3 (13.6 %) OR = 3.21
p = 0.29 p = 0.18
Change in headache intensity
(NRS 0 – 10)
−0.1 ± 1.1 (n = 20) 0.2 ± 1.0 F[40] = 0.30 0.02 ± 1.2 (n = 15) 0.2 ± 1.0 F[33] = 0.28
(−0.2; 0.9) (−0.4; 0.7) p = 0.58 (−0.4; 0.8) (−0.2; 0.9) p = 0.60
Change in days with acute headache
medication in 28 days
−2.0 ± 4.2 −1.3 ± 4.4 F[42] = 0.01 −2.7 ± 4.5 −1.6 ± 4.1 F[35] < 0.01
(−4.2; −0.3) (−4.4; −0.3) p = 0.91 (−4.7; −0.4) (−4.7; −0.3) p = 0.96
Change in MIDAS score −18.7 ± 28.0 −21.8 ± 54.5 F[42] < 0.01 −24.2 ± 29.8 −26.5 ± 53.9 F[35] < 0.01
(−38.6; −0.9) (−39.2; −0.8) p = 0.98 (−43.2; −4.0) (−42.1; −3.7) p = 0.96
Change in HIT-6 score −2.5 ± 6.8 −3.8 ± 5.5 F[42] = 0.12 −3.8 ± 7.1 −3.9 ± 5.69 F[35] = 0.01
(−6.7; −0.7) (−7.3; −1.2) p = 0.73 (−7.8; −1.1) (−7.6; −1.0) p = 0.93
Change refers to change from the 4-week baseline period to the last 4 weeks of the 12-week treatment period. Means, SDs and 95 % confidence intervals are
given. For the responder analysis, numbers of subjects and percent of the total group are given. Significant differences are marked in bold. Number of subjects is
given in parentheses, where different from the total group. Primary outcome parameter: change in headache days/28 days
MIDAS migraine disability assessment, HIT headache impact test, NRS numerical rating scale 0–10
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daily treatment with auricular t-VNS is effective in chronic
migraine.
Both in the 1 Hz and the 25 Hz group the number of
headache days per 28 days decreased significantly by 7.0
and 3.3 days, respectively (PP-analysis, Table 2), with a
significantly larger reduction in the 1 Hz compared to the
25 Hz group (p = 0.035). 29.4 % of the patients in the 1 Hz
group and 13.6 % of the patients in the 25 Hz group
achieved a reduction of more than 50 % in headache days
(“responder”). With an absolute reduction in headache
days per 28 days by 7.0 in the 1 Hz group and a mean
group difference of 2.7 headache days, the effect of auricu-
lar t-VNS was comparable to the effects of topiramate and
onabotulinumtoxin A versus placebo. Previous trials in
chronic migraine with topiramate for 4 months have shown
a reduction in headache days per month of 3.5 and 6.4 days
in the verum group, which exceeded the effect in the
placebo group by 3.7 and 1.7 days, respectively [6, 30]. In
the large PREEMPT trials onabotulinumtoxin A was able
to reduce the number of headache days per month in
chronic migraine patients by 9.0 and 7.8 days after
6 months, which exceeded the placebo effect by 2.3 and
1.4 days, respectively [5, 31]. Compared to previous trials
investigating neurostimulation devices the results are
favorable. In the ONS trials for chronic migraine, reduction
of headache days after 3 months was by 6.7, 5.5 and 6.1 days
in the verum group, which exceeded the sham group by
5.2, 1.6 and 3.1 days, respectively [8–10]. However, none of
these studies reached significance for its primary end point.
Transcutaneous supraorbital neurostimulation has so far
only been tested in episodic migraine, achieving a reduction
by 2.5 headache days from a baseline of 7.8 headache days,
which was 2.3 days more than placebo [11].
It has to be mentioned that the study was planned as a
trial with an active comparator in order to be sure that the
patients were blinded and that we expected that the 25 Hz
stimulation would be more effective than the 1 Hz stimula-
tion, corresponding to the results from the use of invasive
VNS in epilepsy [32, 33]. This means that it is very unlikely
that partial unblinding may have affected the results, as the
local sensation is more intense with 25 Hz stimulation, and
the study physicians expected the 25 Hz stimulation to be
more effective. However, it is not clear why the 1 Hz stimu-
lation was more effective than the 25 Hz stimulation. The
mechanisms by which VNS influences chronic migraine
may be different from those in epilepsy. In addition, activa-
tion of central nervous system structures by stimulation of
thickly myelinated sensory fibers in the auricular branch of
the vagus nerve may require different stimulation patterns
than the cervical branch, which is a mixed nerve with
myelinated and non-myelinated efferent as well as afferent
fibers. As no dose–response or frequency-response data are
available for any neurostimulation method in migraine treat-
ment, the question whether frequency or total number of
stimuli influence the result remains open.
Analgesic effects of electrical low-frequency stimulation
(LFS) in various pain models have been demonstrated in
man and rodents [34]. Electrical pulse series with optimum
frequency of 1 Hz for 20 min significantly suppressed noci-
ceptive signaling and pain perception by approximately
40 % for hours [35, 36]. This phenomenon of long-term
depression (LTD) has been shown in the spinal system
[37–41] and in the craniofacial area [42–44]. Stimulation
parameter of t-VNS in the present study resemble electrical
LFS and could have provoked LTD of nociceptive process-
ing in the spinal trigeminal nucleus that plays a critical role
in migraine pain [45]. Actually, the auriculotemporal nerve,
a branch of the trigeminal nerve, supplies the outer ear and
could, therefore, mediate access of electrically evoked neural
Fig. 4 Mean course of number of headache days per 28 days during
t-VNS treatment. Results of the per protocol set are shown (1 Hz:
n = 17, 25 Hz: n= 22). Values are mean ± SEM. Mean values are also
given in the figure
Table 3 Duration of treatment period and compliance with stimulation during the treatment period
Intention-to-treat analysis Per protocol analysis
1 Hz (n = 22) 25 Hz (n = 24) Group comparison 1 Hz (n = 17) 25 Hz (n = 23) Group comparison
Treatment period (days) 77.9 ± 25.8 85.7 ± 11.4 p = 0.22 89.0 ± 8.4 87.5 ± 7.5 p = 0.67
Average number of stimulated hours per day 3.42 ± 0.59 3.44 ± 0.61 p = 0.69 3.34 ± 0.62 3.44 ± 0.62 p = 0.51
Mean ± SD values are given. Treatment period indicates the number of days between visits 2 and 6. The average number of stimulated hours per day of the
treatment period is given. Patients were requested to stimulate 4 h per day during the treatment period. The real average stimulation time per day was
slightly lower
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signals to brainstem nuclei of the trigeminal nerve [46]. Thus,
LTD could be a mechanism that might, at least, contribute to
the analgesic effect of t-VNS in the present study.
In fact, other stimulation parameters might be even
more effective than the 1 Hz stimulation, and the 25 Hz
stimulation might have been partially active in the present
study, possibly reducing the effect in the group compari-
son. Indeed, 25–30 Hz stimulation has been shown to sig-
nificantly reduce experimental pain in humans [23] and
seizures in rodents [18]. In addition, in the present study
both groups significantly improved in headache-related
disability measures (MIDAS and HIT-6), and reduced
their intake of acute headache medication, although it can-
not be determined if this is due to the placebo effect or
due to stimulation effects in both groups. The missing sig-
nificant difference in the reduction of the MIDAS and
HIT6 between the 1Hz and the 25Hz group is probably
due to the too small sensitivity of these tests in detecting
differences in quality of life. Furthermore, it is unclear if
25 Hz stimulation also have a mood stabilizing effect
which influences the ratings in the used tests.
Furthermore, it is still not clear how vagus nerve
stimulation interferes with migraine generation. One
possibility is a direct or indirect inhibition of nociceptive
trigeminal neurons by vagal activation. Indeed, animal
data show that afferent vagal stimulation can reduce the
activation of nociceptive neurons in the caudal trigemi-
nal nucleus in response to noxious stimulation of the
face or dura [47–49]. This might be due to the existence
of dense reciprocal connections between the spinal tri-
geminal nucleus and the nucleus tractus solitarii (NTS)
which is the major target of vagal afferents [50]. Re-
sponses of spinal trigeminal neurons might also be re-
duced by activation of the descending pain inhibitory
systems. Although this has not been shown directly for
the trigeminal area, animal studies showed that vagal
nerve stimulation can activate descending pain inhibi-
tory systems, probably involving projections from the
NTS to the nucleus raphe magnus and the locus coeruleus,
which are at the origin of serotonergic and noradrenergic
descending pain inhibitory pathways [51]. Alternatively,
VNS might exert migraine prophylactic actions by modify-
ing cortical excitability. Altered cortical excitability in
chronic migraine has been demonstrated in various elec-
trophysiological measurements is thought to contribute to
its pathogenesis [52]. Several lines of evidence indicate that
the cortical excitability is increased in chronic migraine pa-
tients: 1) There is a reduced habituation of the blink reflex
interictally [53]. 2) The magnetic suppression of perceptual
accuracy was decreased in patients with chronic migraine
compared to episodic migraine and controls which may
indicate also a higher cortical excitability [54]. 3) Analysis
of the high frequency somatosensory evoked potentials
showed early response sensitization and late habituation,
most probably due an increased coupling between thal-
amus and cortex in chronic migraine [55]. Afferent vagal
information is relayed via the NTS and the parabrachial
nucleus to several subcortical and cortical regions, including
thalamus, insula and lateral prefrontal cortex. In addition,
the NTS has strong projections to the locus coeruleus and
the nucleus raphe magnus which provide widespread norad-
renergic and serotonergic innervation of the cortex [56].
Modulation of cortical excitability via these pathways is
thought to be important for the anticonvulsant effects of
VNS [33]. Increased GABA levels have been found in the
cerebrospinal fluid of epilepsy patients treated with VNS,
suggesting an increase in inhibitory neurotransmission [57].
Auricular t-VNS increases parasympathetic activity and/or
reduces sympathetic activity [19], which might also affect
cortical excitability, maybe by mechanisms similar to those
assumed for the migraine preventive effects of beta-blocking
agents [58]. In summary, VNS is well positioned to alter cor-
tical excitability, especially to reduce cortical hyperexcitabil-
ity. Direct evidence that this interferes with pain processing
or migraine generation is currently lacking. It would be inter-
esting to repeat the above described experiments which
showed an increased cortical excitability in chronic migraine
under t-VNS stimulation. A third possibility is that the anti-
migraine action of VNS relies on modification of transmitter
release from efferent parasympathetic fibers innervating
Table 4 Overview of adverse events (safety set)
1 Hz (n = 22) 25 Hz (n = 24)
Number of events Number of patients (%) Number of events Number of patients (%)
Treatment emergent AEs 67 17 (77.3 %) 112 19 (79.2 %)
Treatment-related AEs 39 11 (50.0 %) 76 17 (70.8 %)
Stimulation site treatment-related TEAEs 31 10 (45.5 %) 70 17 (70.8 %)
All serious AEs (including pre-treatment SAEs) 2 2 (9.1 %) 0 0
Serious treatment emergent AEs 2 2 (9.1 %) 0 0
Serious treatment-related AEs 0 0 0 0
Treatment-related AEs leading to discontinuation of study 8 4 (18.2 %) 4 1 (4.2 %)
Death 0 0 0 0
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dural vessels, e.g. fibers stemming from the spheno-palatine
ganglion. The release of neurotransmitters, especially calci-
tonin-gene related peptide (CGRP), at dural vessels with
subsequent neurogenic inflammation and sensitization of
primary afferents is thought to play an important role in
migraine pathophysiology [59]. Parasympathetic fibres in-
nervating the dura mater release vasoactive intestinal poly-
peptide (VIP) and pituitary adenylate cyclase-activating
polypeptide (PACAP), which are potent vasodilatators and
thought to contribute to sensitization of nociceptive trigemi-
nal primary afferents. Increased peripheral blood VIP levels
have been detected in chronic migraine [60], and intraven-
ous administration of PACAP has been shown to induce
migrainous headache in migraine patients [61], suggesting
that both transmitters are related to migraine patho-
physiology. Although auricular t-VNS stimulates only vagal
afferents, there are close connections between afferent and
efferent parasympathetic brainstem centers, making an in-
fluence of VNS on dural efferents likely.
A major practical advantage of auricular t-VNS is good
tolerability and safety. For comparison, in the pooled topir-
amate trial analysis, 1 out of 4 patients (25 %) dropped out
because of intolerable adverse effects [62]. In our study
only 3 of 46 patients (7 %) dropped out due to side effects
of t-VNS. All three cases occurred early in the study and
were due to stimulation site ulcer which later in the study
could be prevented by appropriate skin care. Another ad-
vantage of t-VNS therapy is that it can be combined with
any other drug treatment without risking cumulative ad-
verse effects or pharmacodynamic interactions. In addition,
auricular t-VNS allows patients to continue routine activ-
ities, leading to a high compliance with stimulation times
(around 85 % on average). However, long-term effects and
sustainability of efficacy of t-VNS are still unknown and
need to be demonstrated in appropriate open-label trials.
Conclusions
In conclusion, the present parallel-group randomized con-
trolled trial, provides evidence that auricular t-VNS at 1 Hz
for 4 h daily is effective for chronic migraine prevention
over 3 months. The absolute reduction in headache days
(7.0) and the difference between groups (2.7 headache days)
is comparable to the effects of topiramate and onabotuli-
num toxin A in chronic migraine prevention. The t-VNS
treatment also results in a meaningful improvement in the
quality of life as assessed by MIDAS and HIT 6. The safety
profile was favourable and compliance with daily stimula-
tion was high.
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